local_hospital

Roskilde University

Address
lock Available on a paid plan

Hematology and Cancer Research

At Roskilde University, the Department of Hematology H60 supports a broad range of oncology and hematology trials focused on cancers such as acute myeloid leukemia, lymphoma, breast cancer, solid tumors, and glioblastoma. These studies are designed to test new treatment approaches, improve response monitoring, and evaluate how well emerging therapies work in people with difficult-to-treat disease.

  • Studies in blood cancers and solid tumors aim to improve treatment effectiveness and long-term disease control
  • Research includes lymphoma, leukemia, and advanced cancer types with limited treatment options
  • Trials also explore better ways to measure treatment response and guide personalized care

This research area combines cancer treatment development with practical efforts to refine diagnosis and monitoring for patients.

Cardiovascular and Heart Failure Studies

A major focus at this site is cardiovascular disease research, including heart failure, atrial fibrillation, myocardial infarction, aortic valve stenosis, and atherosclerotic disease. The trials are aimed at improving prevention, reducing complications, and identifying better treatment strategies for people at risk of serious heart-related events.

  • Research on heart failure examines ways to improve symptoms and reduce hospitalizations
  • Studies in coronary disease and stroke prevention look at lowering major cardiovascular risks
  • Several trials assess more personalized approaches to antithrombotic and heart failure care

These trials reflect a strong interest in practical therapies that may improve survival and daily functioning for patients with complex cardiovascular conditions.

Respiratory and Lung Disease Research

The site also contributes to respiratory medicine through studies in chronic obstructive pulmonary disease, asthma, community-acquired pneumonia, and idiopathic pulmonary fibrosis. The purpose of this work is to evaluate new treatments, reduce flare-ups, and better understand how lung disease progresses in different patient groups.

  • Trials in COPD and asthma focus on preventing exacerbations and improving day-to-day breathing control
  • Research in pulmonary fibrosis and pneumonia explores treatment effectiveness and clinical recovery
  • Some studies aim to improve outcomes for patients with complicated or treatment-resistant lung disease

Overall, this is an active field for testing therapies that may ease symptoms and reduce the burden of chronic lung illness.

Immune, Inflammatory, and Gastrointestinal Conditions

A substantial part of the trial portfolio addresses immune system diseases, inflammatory disorders, and gastrointestinal disease, including Crohn’s disease, primary biliary cholangitis, idiopathic inflammatory myopathy, and calcinosis cutis. These studies aim to improve symptom control, support remission, and test whether new therapies can better manage chronic immune-related conditions.

  • Research in Crohn’s disease focuses on improving disease control and treatment targets
  • Trials in autoimmune and inflammatory disorders assess safety and effectiveness of newer therapies
  • Work in liver and skin-related immune disease explores better ways to reduce disease activity

This area highlights a strong commitment to therapies that may help patients living with long-term inflammatory illness.

Neurology, Rare Disease, and Mental Health Research

Roskilde University is also involved in studies of neurological disorders, rare diseases, and mental health, including amyotrophic lateral sclerosis, multiple system atrophy, migraine, postpartum depression, and inherited metabolic conditions such as phenylketonuria and Pompe disease. The aim is to test novel therapies, improve quality of life, and support better management of conditions that often have limited treatment options.

  • Studies in neurology evaluate treatments for progressive disorders affecting movement and function
  • Research in rare metabolic diseases looks at safer and more effective long-term management
  • Mental health work includes efforts to prevent or reduce postpartum depression

This portfolio shows a clear interest in both high-need chronic diseases and uncommon conditions requiring specialized care.

Diagnostics, Procedures, and Acute Care

Another important research theme involves diagnostic techniques, acute care, and treatment support across several specialties. Trials at the site examine approaches for stroke, critical illness, abdominal surgery, fractures, and other urgent conditions, with the goal of improving diagnosis, symptom relief, and clinical decision-making.

  • Studies assess better ways to detect disease and monitor treatment response
  • Acute care research looks at improving outcomes in emergency and intensive care settings
  • Procedural studies focus on reducing pain, complications, and recovery time

These trials reflect a practical research focus on making everyday clinical care safer and more effective for patients across a wide range of conditions.

Site Overview

assignment
62
connected trials
corporate_fare
38
sponsors
science
142
IMPs

Activity Indicator

Last 6 months

7
Trials started
+17% vs previous period.
6
Trials started 6–12 months ago
62
Total trials linked
Highly Active
trending_upGrowing+17%
2
3
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 21 therapeutic areas and 15 of 142 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 134 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
43
Sponsors (total)
38
Active sponsors
27

Sponsor Network

Top 27 by active trials.

lock +26 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +9 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
62
Outperforms 90% of sites
public
Therapeutic diversity
23areas
Outperforms 93% of sites
groups
Sponsor diversity
38sponsors
Outperforms 91% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Roskilde University

lock Showing 1 of 62 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.Cell to Cure ApSPhase IINot RecruitingMar 2026

IMP list

lock Showing 1 of 142 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Sodium Chloride7Unknown2020-10-302025-12-17

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.